Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet; Karolinska University Hospital
• Collaborator: Karolinska University Hospital
• Treatments: Ganciclovir; Valganciclovir

Criteria

Inclusion Criteria:

• Glioblastoma grade IV

• Cytomegalovirus detected in tumor

• At least 90% resection of tumor

Exclusion Criteria:

• Decreased kidney function

• Pregnancy

• Neutropenia

• Thrombocytopenia

• Patient not tolerating the drug